Trial Profile
A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2017
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Oblimersen (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 30 Jan 2009 Primary outcome amended as reported by ClinicalTrials.gov.
- 16 Aug 2005 New trial record.